-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on CASI Pharmaceuticals, Lowers Price Target to $4

Benzinga·04/09/2025 11:20:18
Listen to the news
HC Wainwright & Co. analyst Sean Lee maintains CASI Pharmaceuticals (NASDAQ:CASI) with a Buy and lowers the price target from $6 to $4.